Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: August 2010

Topiramate

Suggested reading
Ben-Menachem, E, Axelsen, M, Johanson, EH, Stagge, A, Smith, U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity Research 2003; 11: 556–562.
Biton, V, Bourgeois, BF. Topiramate in patients with juvenile myoclonic epilepsy. Archives of Neurology 2005; 62: 1705–1708.
Biton, V, Montouris, GD, Ritter, F, Riviello, JJ, Reife, R, Lim, P, Pledger, G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330–1337.
Faught, E, Wilder, BJ, Ramsay, RE, Reife, RA, Kramer, LD, Pledger, GW, Karim, RM. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46: 1684–1690.
Glauser, TA, Clark, PO, Strawsburg, R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324–1328.
Groeper, K, McCann, ME. Topiramate and metabolic acidosis: a case series and review of the literature. Paediatric Anaesthesia 2005; 15: 167–170.
Hamer, HM, Knake, S, Schomburg, U, Rosenow, F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000; 54: 230–232.
Johannessen, Landmark C, Patsalos, PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.
Meador, KJ, Loring, DW, Hulihan, JF, Kamin, M, Karim, R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60: 1483–1488.
Meador, KJ, Loring, DW, Vahle, VJ, Ray, PG, Werz, MA, Fessler, AJ, Ogrocki, P, Schoenberg, MR, Miller, JM, Kustra, RP. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108–2114.
Mirza, N, Marson, AG, Pirmohamed, M. Effect of topiramate on acid-base balance: extent, mechanism and effects. British Journal of Clinical Pharmacology 2009; 68: 655–661.
Mula, M, Trimble, MR, Thompson, P, Sander, JW. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003; 60: 1104–1107.
Ohman, I, Sabers, A, Flon, P, Luef, G, Tomson, T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Research 2009; 87: 124–129.
Patsalos, PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
Privitera, M, Fincham, R, Penry, J, Reife, R, Kramer, L, Pledger, G, Karim, R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996; 46: 1678–1683.
Sachdeo, RC, Glauser, TA, Ritter, F, Reife, R, Lim, P, Pledger, G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999; 52: 1882–1887.